NCT02801383View on ClinicalTrials.gov

Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Cervical HPV-16 and / or HPV-18 Infection
Interventions
DRUG

Yallaferon®， the recombinant human interferon α-2b gel

OTHER

gel without active ingredient

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY